Hepatitis B virus e antigen-negative chronic infection. Treatment based on glutamic pyruvic transaminase and hepatitis B virus deoxyribonucleic acid cut-off values

Lai, 2007, The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points, Ann Intern Med, 147, 58, 10.7326/0003-4819-147-1-200707030-00010 2000 Goldstein, 2005, A mathematical model to estimate global hepatitis B disease burden and vaccination impact, Int J Epidemiol, 34, 1329, 10.1093/ije/dyi206 Hadziyannis, 2001, Hepatitis B e antigen-negative chronic hepatitis B, Hepatology, 34, 617, 10.1053/jhep.2001.27834 Brunetto, 1989, Identification of HBV variants which cannot produce precore derived HBeAg and may be responsible for severe hepatitis, Ital J Gastroenterol, 21, 151 Carman, 1989, Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection, Lancet, 334, 588, 10.1016/S0140-6736(89)90713-7 Funk, 2002, World-wide epidemiology of HBeAg negative chronic hepatitis B and associated precore and core promoter variants, J Viral Hepatol, 9, 52, 10.1046/j.1365-2893.2002.00304.x Chu, 2003, Prevalence of HBV precore/core promoter variants in the United States, Hepatology, 38, 619, 10.1053/jhep.2003.50352 Rizzetto, 1998, Viral hepatitis in the third millennium, Res Virol, 149, 251, 10.1016/S0923-2516(99)89002-5 Rizzetto, 2008, Chronic HBV-related liver disease, Mol Aspects Med, 29, 72, 10.1016/j.mam.2007.09.013 Zarski, 2006, Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases, J Hepatol, 45, 355, 10.1016/j.jhep.2006.03.007 Gómez Rodríguez, 2013, Characteristics of patients with chronic hepatitis B virus infection. Analysis of a series of 474 patients, Gastroenterol Hepatol, 36, 243, 10.1016/j.gastrohep.2012.10.006 Poves Martínez, 2012, Incidencia diagnóstica de AgHBs positivo. Características epidemiológicas, clínicas y virológicas, Rev Esp Enferm Dig, 104, 10, 10.4321/S1130-01082012000100003 Martín-Mateos, 2014, HBeAg-positive chronic hepatitis B treatment with oral antiviral agents: experience and results in clinical practice, Gastroenterol Hepatol, 37, 280, 10.1016/j.gastrohep.2013.11.011 Lampertico, 1997, A randomized controlled trial of a 24 month course of interferon alpha2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum, Hepatology, 26, 1621, 10.1002/hep.510260634 Mangia, 1996, Pathogenesis of chronic liver disease in patients with chronic hepatitis B virus infection without serum HBeAg, Dig Dis Sci, 41, 2447, 10.1007/BF02100141 Torre, 2009, Clinical and virological survey of patients with hepatitis B surface antigen in an Italian region: clinical considerations and disease burden, J Med Virol, 81, 1882, 10.1002/jmv.21523 Kondili, 2005, Clinical and molecular characterization of chronic hepatitis B in Albania: a country that is still highly endemic for HBV infection, J Med Virol, 75, 20, 10.1002/jmv.20231 Papatheodoridis, 2001, The long-term outcome of interferon-treated and untreated patients with HBeAg-negative chronic hepatitis B, J Hepatol, 34, 306, 10.1016/S0168-8278(00)00094-5 Tassopoulos, 1999, Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B Lamivudine precore mutant group, Hepatology, 29, 889, 10.1002/hep.510290321 Chan, 2000, Hepatitis B. e antigen negative chronic hepatitis B in Hong Kong, Hepatology, 31, 763, 10.1002/hep.510310330 Yoo, 2003, Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea, J Hepatol, 38, 98, 10.1016/S0168-8278(02)00349-5 Cotler, 2009, Hepatitis B seroprevalence and disease characteristics in an urban Chinatown community, Clin Gastroenterol Hepatol, 7, 776, 10.1016/j.cgh.2009.03.023 Chachá, 2011, Clinical, demographic and epidemiological characteristics of patients with hepatitis B followed at a university hospital in southeastern Brazil: predominance of HBeAg negative cases, Rev Soc Bras Med Trop, 44, 13, 10.1590/S0037-86822011000100004 Prati, 2002, Updated definitions of healthy ranges for serum alanine aminotransferase levels, Ann Intern Med, 137, 1, 10.7326/0003-4819-137-1-200207020-00006 Schwimmer, 2010, SAFETY study: Alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease, Gastroenterology, 138, 1357, 10.1053/j.gastro.2009.12.052 Zheng, 2012, Upper limits of normal for serum alanine aminotransferase levels in Chinese Han population, PLoS ONE, 7, e43736, 10.1371/journal.pone.0043736 Gui, 2010, Significant histopathology in Chinese chronic hepatitis B patients with persistently high-normal alanine aminotransferase, J Viral Hepat, 17, 44, 10.1111/j.1365-2893.2010.01270.x Kim, 2004, Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study, Br Med J, 328, 983, 10.1136/bmj.38050.593634.63 Assy, 2009, Lower baseline ALT cut-off values and HBV DNA levels better differentiate HBeAg(−) chronic hepatitis B patients from inactive chronic carriers, World J Gastroenterol, 15, 3025, 10.3748/wjg.15.3025 Ijaz, 2011, Revised cutoff values of ALT and HBV DNA level can better differentiate HBeAg(−) chronic inactive HBV patients from active carriers, Virol J, 8, 86, 10.1186/1743-422X-8-86 Hu, 2010, Histologic evidence of active liver injury in chronic hepatitis B patients with normal range or minimally elevated alanine aminotransferase levels, J Clin Gastroenterol, 44, 510, 10.1097/MCG.0b013e3181d34c65 Kumar, 2008, Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT, Gastroenterology, 134, 1376, 10.1053/j.gastro.2008.02.075 Papatheodoridis, 2008, Is there a meaningful serum HBV DNA cut-off level for therapeutic decisions in HBeAg-negative chronic hepatitis B virus infection?, Hepatology, 48, 1451, 10.1002/hep.22518 Chen, 2012, Serial HBV DNA levels in patients with persistently normal transaminase over 10 years following spontaneous HBeAg seroconversion, J Viral Hepat, 19, 138, 10.1111/j.1365-2893.2011.01450.x Tai, 2009, Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time, Hepatology, 49, 1859, 10.1002/hep.22878 Chen, 2010, Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver related death, Gastroenterology, 138, 1747, 10.1053/j.gastro.2010.01.042 Chao, 2014, Systematic review with meta-analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase ≤40IU/L and significant hepatic fibrosis, Aliment Pharmacol Ther, 39, 349, 10.1111/apt.12590 1994, Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C, Hepatology, 1, 15 Viganò, 2011, Dual cut-off transient elastography to assess liver fibrosis in chronic hepatitis B: a cohort study with internal validation, Aliment Pharmacol Ther, 34, 353, 10.1111/j.1365-2036.2011.04722.x Guardiola Arévalo, 2017, Características y evolución de la infección crónica por virus de la hepatitis B antígeno e negativo, Gastroenterol Hepatol, 40, 59, 10.1016/j.gastrohep.2016.11.002 Lin, 2007, Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels, Hepatology, 45, 1193, 10.1002/hep.21585 Yuen, 2005, Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications, Gut, 54, 1610, 10.1136/gut.2005.065136 Seist, 1975, Aspartate aminotransferase and alanine aminotransferase activities in plasma: statistical distributions, individual variations, and reference values, Clin Chem, 21, 1077, 10.1093/clinchem/21.8.1077 Sherman, 1991, Alanine aminotransferase in clinical practice. A review, Arch Intern Med, 151, 260, 10.1001/archinte.1991.00400020036008 Van der Poorten, 2007, Liver disease in adolescents: a cohort study of high-risk individuals, Hepatology, 46, 1750, 10.1002/hep.21918 Papatheodoridis, 2012, Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review, J Hepatol, 57, 196, 10.1016/j.jhep.2011.11.030 2012, EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection, J Hepatol, 57, 167, 10.1016/j.jhep.2012.02.010 Brunetto, 2010, Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers, Gastroenterology, 139, 483, 10.1053/j.gastro.2010.04.052